Health Economics›T-cell acute lymphoblastic leukemia pediatric›Upfront therapy

Upfront therapy

T-cell acute lymphoblastic leukemia pediatric · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
COG AALL1231 Protocol Arm A N/A - intrathecal component	—	R 66 727	56d	—	—	—	—	—
COG AALL0434 protocol N/A - intrathecal component Partial	—	R 45 735	84d	—	—	—	—	—

2 of 2 regimens shown